Mersana Therapeutics, Inc.2024财年实现净利润-69.19百万美元，同比增加59.77%

市场透视2025-03-09

3月9日，Mersana Therapeutics, Inc.（MRSN.US）公布财报，公告显示公司2024财年净利润为-69.19百万美元，同比增加59.77%；其中营业收入为40.50百万美元，同比增加9.88%，每股基本收益为-0.56美元。从资产负债表来看，Mersana Therapeutics, Inc.（MRSN.US）总负债1.54亿美元，其中短期债务16.40百万美元，资产负债...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2518244098?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-09 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2518244098","market":"us","top_or_hot":-1,"title":"Mersana Therapeutics, Inc.2024财年实现净利润-69.19百万美元，同比增加59.77%","media":"市场透视","content":"<div>\n<p>3月9日，Mersana Therapeutics, Inc.（MRSN.US）公布财报，公告显示公司2024财年净利润为-69.19百万美元，同比增加59.77%；其中营业收入为40.50百万美元，同比增加9.88%，每股基本收益为-0.56美元。从资产负债表来看，Mersana Therapeutics, Inc.（MRSN.US）总负债1.54亿美元，其中短期债务16.40百万美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000233abef9846&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mersana Therapeutics, Inc.2024财年实现净利润-69.19百万美元，同比增加59.77%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMersana Therapeutics, Inc.2024财年实现净利润-69.19百万美元，同比增加59.77%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-09 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000233abef9846&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月9日，Mersana Therapeutics, Inc.（MRSN.US）公布财报，公告显示公司2024财年净利润为-69.19百万美元，同比增加59.77%；其中营业收入为40.50百万美元，同比增加9.88%，每股基本收益为-0.56美元。从资产负债表来看，Mersana Therapeutics, Inc.（MRSN.US）总负债1.54亿美元，其中短期债务16.40百万美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000233abef9846&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000233abef9846&s=b","article_id":"2518244098","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000233abef9846&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2518244098","pubTimestamp":1741449671,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月9日，Mersana Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-69.19百万美元，同比增加59.77%；其中营业收入为40.50百万美元，同比增加9.88%，每股基本收益为-0.56美元。从资产负债表来看，Mersana Therapeutics, Inc.总负债1.54亿美元，其中短期债务16.40百万美元，资产负债比为0.95，流动比率为0.03。机构评级：截至2025年3月9日，当前有7家机构对Mersana Therapeutics, Inc.目标价做出预测，其中目标均价为4.71美元，其中最低目标价为1.00美元，最高目标价为9.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","MRSN":"Mersana Therapeutics Inc."},"translate_title":"Mersana Therapeutics, Inc. achieved net profits of-US $69.19 million in fiscal year 2024, a year-on-year increase of 59.77%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":0.6,"MRSN":0.6},"content_text":"3月9日，Mersana Therapeutics, Inc.（MRSN.US）公布财报，公告显示公司2024财年净利润为-69.19百万美元，同比增加59.77%；其中营业收入为40.50百万美元，同比增加9.88%，每股基本收益为-0.56美元。从资产负债表来看，Mersana Therapeutics, Inc.（MRSN.US）总负债1.54亿美元，其中短期债务16.40百万美元，资产负债比为0.95，流动比率为0.03。机构评级：截至2025年3月9日，当前有7家机构对Mersana Therapeutics, Inc.目标价做出预测，其中目标均价为4.71美元，其中最低目标价为1.00美元，最高目标价为9.00美元。公司简介：梅莎娜制药有限公司是一家临床阶段的生物制药公司，利用其差异化和专有的 ADC 平台来开发具有更高耐受性和更多机会为患者带来有意义的临床益处的靶向药物。 该公司的早期项目包括 XMT-1660（一种针对 B7-H4 的 Dolasynthen ADC）以及 XMT-2056（一种使用该公司的Immunosynthen平台开发的 STING 激动剂 ADC，针对人表皮生长因子受体 2 的新表位）。 还有两个早期临床前候选药物 XMT-2068 和 XMT-2175，两者都利用该公司的Immunosynthen 平台并针对肿瘤相关抗原。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518244098","isCrawlerRequest":true}